A citation-based method for searching scientific literature

Adam N Guterres, Jessie Villanueva. Oncogene 2020
Times Cited: 10







List of co-cited articles
27 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Patrick J Killela, Zachary J Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A Diaz, Allan H Friedman, Henry Friedman, Gary L Gallia, Beppino C Giovanella,[...]. Proc Natl Acad Sci U S A 2013
848
40


Cancer-associated TERT promoter mutations abrogate telomerase silencing.
Kunitoshi Chiba, Joshua Z Johnson, Jacob M Vogan, Tina Wagner, John M Boyle, Dirk Hockemeyer. Elife 2015
142
30

Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
Robert J A Bell, H Tomas Rube, Alex Kreig, Andrew Mancini, Shaun D Fouse, Raman P Nagarajan, Serah Choi, Chibo Hong, Daniel He, Melike Pekmezci,[...]. Science 2015
287
30

Specific association of human telomerase activity with immortal cells and cancer.
N W Kim, M A Piatyszek, K R Prowse, C B Harley, M D West, P L Ho, G M Coviello, W E Wright, S L Weinrich, J W Shay. Science 1994
30

Therapeutic nanoparticles for drug delivery in cancer.
Kwangjae Cho, Xu Wang, Shuming Nie, Zhuo Georgia Chen, Dong M Shin. Clin Cancer Res 2008
20


Suicide gene‑armed measles vaccine virus for the treatment of AML.
Stefanie Maurer, Helmut R Salih, Irina Smirnow, Ulrich M Lauer, Susanne Berchtold. Int J Oncol 2019
10
20

Deciphering the Mechanism of Action Involved in Enhanced Suicide Gene Colon Cancer Cell Killer Effect Mediated by Gef and Apoptin.
Blanca Cáceres, Alberto Ramirez, Esmeralda Carrillo, Gema Jimenez, Carmen Griñán-Lisón, Elena López-Ruiz, Yaiza Jiménez-Martínez, Juan A Marchal, Houria Boulaiz. Cancers (Basel) 2019
11
20

Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma.
Bingtao Tang, Zong Sheng Guo, David L Bartlett, David Z Yan, Claire P Schane, Diana L Thomas, Jia Liu, Grant McFadden, Joanna L Shisler, Edward J Roy. Clin Cancer Res 2020
12
20

Therapeutic strategies for targeting telomerase in cancer.
Xing Chen, Wen-Jian Tang, Jing Bo Shi, Ming Ming Liu, Xin-Hua Liu. Med Res Rev 2020
15
20

MicroRNAs and complex diseases: from experimental results to computational models.
Xing Chen, Di Xie, Qi Zhao, Zhu-Hong You. Brief Bioinform 2019
201
20

Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer.
Bruno Bernardes de Jesus, Elsa Vera, Kerstin Schneeberger, Agueda M Tejera, Eduard Ayuso, Fatima Bosch, Maria A Blasco. EMBO Mol Med 2012
211
20


Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression.
Ekta Khattar, Pavanish Kumar, Chia Yi Liu, Semih Can Akıncılar, Anandhkumar Raju, Manikandan Lakshmanan, Julien Jean Pierre Maury, Yu Qiang, Shang Li, Ern Yu Tan,[...]. J Clin Invest 2016
79
20

Non-canonical NF-κB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation.
Yinghui Li, Qi-Ling Zhou, Wenjie Sun, Prashant Chandrasekharan, Hui Shan Cheng, Zhe Ying, Manikandan Lakshmanan, Anandhkumar Raju, Daniel G Tenen, Shi-Yuan Cheng,[...]. Nat Cell Biol 2015
117
20

Highly recurrent TERT promoter mutations in human melanoma.
Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
20

Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner.
Andrew Mancini, Ana Xavier-Magalhães, Wendy S Woods, Kien-Thiet Nguyen, Alexandra M Amen, Josie L Hayes, Christof Fellmann, Michael Gapinske, Andrew M McKinney, Chibo Hong,[...]. Cancer Cell 2018
43
20

Therapeutic Targeting of Telomerase.
Kathrin Jäger, Michael Walter. Genes (Basel) 2016
61
20

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N Louis, Arie Perry, Guido Reifenberger, Andreas von Deimling, Dominique Figarella-Branger, Webster K Cavenee, Hiroko Ohgaki, Otmar D Wiestler, Paul Kleihues, David W Ellison. Acta Neuropathol 2016
20

Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers.
Josh Lewis Stern, Dan Theodorescu, Bert Vogelstein, Nickolas Papadopoulos, Thomas R Cech. Genes Dev 2015
97
20

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
20

TERT promoter mutations in familial and sporadic melanoma.
Susanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, Christine Fischer, Antje Sucker, Andreas Gast, Stephanie Kadel, Iris Moll, Eduardo Nagore, Kari Hemminki,[...]. Science 2013
20

Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer.
Ricardo Leão, Joana Dias Apolónio, Donghyun Lee, Arnaldo Figueiredo, Uri Tabori, Pedro Castelo-Branco. J Biomed Sci 2018
74
20

TERT regulates cell survival independent of telomerase enzymatic activity.
Ying Cao, He Li, Siddhartha Deb, Jun-Ping Liu. Oncogene 2002
175
20

Telomerase: central regulator of all of the hallmarks of cancer.
Kee Chung Low, Vinay Tergaonkar. Trends Biochem Sci 2013
155
20

A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small-cell lung cancer.
A A Chiappori, T Kolevska, D R Spigel, S Hager, M Rarick, S Gadgeel, N Blais, J Von Pawel, L Hart, M Reck,[...]. Ann Oncol 2015
85
20

Diagnostic impact of nuclear DNA content and proliferative activity in benign and malignant melanocytic lesions.
Z R Steinbeck, K M Heselmeyer, B Gerlach, V Björnhagen, G U Auer. Melanoma Res 1996
9
11


Automated quantification of MART1-verified Ki67 indices by digital image analysis in melanocytic lesions.
Patricia Switten Nielsen, Rikke Riber-Hansen, Jakob Raundahl, Torben Steiniche. Arch Pathol Lab Med 2012
20
10

Major response to imatinib mesylate in KIT-mutated melanoma.
F Stephen Hodi, Philip Friedlander, Christopher L Corless, Michael C Heinrich, Suzanne Mac Rae, Andrea Kruse, Jyothi Jagannathan, Annick D Van den Abbeele, Elsa F Velazquez, George D Demetri,[...]. J Clin Oncol 2008
297
10



High concordance of BRAF mutational status in matched primary and metastatic melanoma.
David Cormican, Ciaran Kennedy, Sandra Murphy, Reiltin Werner, Derek G Power, Cynthia C B B Heffron. J Cutan Pathol 2019
2
50

Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.
Sebastian Costa, Michelle Byrne, Daniel Pissaloux, Veronique Haddad, Sandrine Paindavoine, Luc Thomas, Francois Aubin, Thierry Lesimple, Florent Grange, Bertille Bonniaud,[...]. Am J Surg Pathol 2016
57
10

The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas.
Arnaud Uguen, Marie Uguen, Briac Guibourg, Matthieu Talagas, Pascale Marcorelles, Marc De Braekeleer. Appl Immunohistochem Mol Morphol 2018
7
14

SP174 Antibody Lacks Specificity for NRAS Q61R and Cross-Reacts With HRAS and KRAS Q61R Mutant Proteins in Malignant Melanoma.
Anna Felisiak-Goląbek, Shingo Inaguma, Artur Kowalik, Bartosz Wasąg, Zeng-Feng Wang, Sebastian Zięba, Liliana Pięciak, Janusz Ryś, Janusz Kopczynski, Maarit Sarlomo-Rikala,[...]. Appl Immunohistochem Mol Morphol 2018
12
10

Usefulness of immunocytochemistry for the detection of the BRAF(V600E) mutation in circulating tumor cells from metastatic melanoma patients.
Véronique Hofman, Marius Ilie, Elodie Long-Mira, Damien Giacchero, Catherine Butori, Bérengère Dadone, Eric Selva, Virginie Tanga, Thierry Passeron, Gilles Poissonnet,[...]. J Invest Dermatol 2013
31
10

KIT as an Oncogenic Driver in Melanoma: An Update on Clinical Development.
Da Meng, Richard D Carvajal. Am J Clin Dermatol 2019
24
10

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.
Emeline Colomba, Zofia Hélias-Rodzewicz, Andreas Von Deimling, Cristi Marin, Nathalie Terrones, Dominique Pechaud, Sylvie Surel, Jean-François Côté, Frédérique Peschaud, David Capper,[...]. J Mol Diagn 2013
126
10

Melanoma-associated antigens recognized by cytotoxic T lymphocytes.
A F Kirkin, K Dzhandzhugazyan, J Zeuthen. APMIS 1998
48
10

Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.
Thomas Wiesner, Heinz Kutzner, Lorenzo Cerroni, Martin C Mihm, Klaus J Busam, Rajmohan Murali. Pathology 2016
68
10

Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions.
Klaus J Busam, Heinz Kutzner, Lorenzo Cerroni, Thomas Wiesner. Am J Surg Pathol 2014
83
10

Analyses of molecular and histopathologic features and expression of PRAME by immunohistochemistry in mucosal melanomas.
Aimi Toyama, Lianne Siegel, Andrew C Nelson, Mufaddal Najmuddin, Lihong Bu, Rebecca LaRue, Christine Henzler, Emiro Caicedo-Granados, Alessio Giubellino, Faqian Li. Mod Pathol 2019
11
10

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
David Capper, Matthias Preusser, Antje Habel, Felix Sahm, Ulrike Ackermann, Genevieve Schindler, Stefan Pusch, Gunhild Mechtersheimer, Hanswalter Zentgraf, Andreas von Deimling. Acta Neuropathol 2011
356
10

Giemsa is the optimal counterstain for immunohistochemical detection of BRAF V600E mutation status in pigmented melanomas.
Sanjita Ravishankar, Priyadharsini Nagarajan, Jonathan L Curry, Michael T Tetzlaff, Doina Ivan, Carlos A Torres-Cabala, Phyu P Aung, Victor G Prieto. J Cutan Pathol 2016
6
16

Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
J A Reed, F Loganzo, C R Shea, G J Walker, J F Flores, J M Glendening, J K Bogdany, M J Shiel, F G Haluska, J W Fountain. Cancer Res 1995
266
10

p16 Range of expression in dermal predominant benign epithelioid and spindled nevi and melanoma.
Gabriel Oaxaca, Steven D Billings, Jennifer S Ko. J Cutan Pathol 2020
1
100

Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type.
Carlos A Torres-Cabala, Wei-Lien Wang, Jonathan Trent, Dan Yang, Su Chen, John Galbincea, Kevin B Kim, Scott Woodman, Michael Davies, Jose A Plaza,[...]. Mod Pathol 2009
137
10

Proliferation indices of phosphohistone H3 and Ki67: strong prognostic markers in a consecutive cohort with stage I/II melanoma.
Patricia S Nielsen, Rikke Riber-Hansen, Trine O Jensen, Henrik Schmidt, Torben Steiniche. Mod Pathol 2013
59
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.